Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name ANRIL
   Synonyms CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS
   Region GRCh38_9:21994778-22121097    Sequence
   Ensembl ENSG00000240498
   RefSeq NR_003529
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name lung cancer
   ICD-0-3 C34  
   Methods qPCR, RNAi, Western blot, Cell apoptosis assay etc.
   Sample cell lines (H460, H1975, HCT116, BEAS2B)
   Expression Pattern up-regulated
   Function Description

The expression level of ANRIL was increased up to 13.6-fold by PLD inhibition in H460 human lung cancer cells. Moreover, knockdown of ANRIL using its specific small-interfering RNA significantly suppressed PLD inhibition-induced apoptosis. Collectively, our findings showed that ANRIL is an lncRNA responsible in anti-tumorigenesis caused by PLD inhibition and combined incorporation of ANRIL into PLD inhibition-induced anti-tumorigenic signaling network could be a new effective therapeutic approach for controlling lung cancer.

   Pubmed ID 25964559
   Year 2015
   Title Down-regulation of Phospholipase D Stimulates Death of Lung Cancer Cells Involving Up-regulation of the Long ncRNA ANRIL.
   External Links
   Links for  ANRIL GenBank       HGNC       lncrnadb       Noncode
   Links for  lung cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.